Aduhelm

Federal watchdog cites concerns with FDA’s accelerated approval process
BioPharma Dive
Wed, 01/15/25 - 11:48 pm
HHS
FDA
accelerated approvals
Aduhelm
Biogen
Aduhelm and an expensive failure to launch
Pharmaphorum
Tue, 03/26/24 - 04:25 pm
Biogen
Alzheimer's disease
Aduhelm
drug launches
FDA guidelines consider amyloid reduction 'reasonably likely' to predict Alzheimer's benefit
Fierce Biotech
Tue, 03/12/24 - 11:34 am
Biogen
Eisai
Aduhelm
FDA
Alzheimer's disease
amyloid
Eli Lilly
donanemab
Biogen abandons Aduhelm efforts, focuses on Eisai-partnered Leqembi and pipeline drugs
Fierce Pharma
Wed, 01/31/24 - 11:50 am
Biogen
Aduhelm
Leqembi
Alzheimer's disease
Biogen's Aduhelm headache returns as appeals court revives part of investor lawsuit
Fierce Pharma
Thu, 10/12/23 - 05:18 pm
Biogen
Aduhelm
legal
Eisai
Alzheimer's disease
6 Drugs Approved Despite Failed Trials or Minimal Data
BioSpace
Mon, 10/9/23 - 11:10 am
Ipsen
Sohonos
Sarepta Therapeutics
Elevidys
Biogen
Qalsody
Eisai
Aduhelm
Jazz Pharma
PharmaMar
Zepzelca
Acadia Pharma
Nuplazid
After quitting FDA adcomm in protest of Aduhelm decision, Harvard's Aaron Kesselheim finds agency has an approval bias
Fierce Pharma
Mon, 07/31/23 - 10:07 am
FDA
Biogen
Aduhelm
Alzheimer's disease
advisory committees
drug approvals
Massachusetts judge dismisses lawsuit against Biogen over failed launch of Alzheimer's drug Aduhelm
Endpoints
Thu, 03/30/23 - 11:05 pm
Massachusetts
Biogen
Aduhelm
legal
Biogen's head of neurodegeneration leaves
Fierce Biotech
Fri, 03/17/23 - 10:03 am
Biogen
women executives
Aduhelm
Alzheimer's disease
VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm
Endpoints
Mon, 03/13/23 - 04:44 pm
VHA
Eisai
Biogen
Leqembi
Aduhelm
Alzheimer's disease
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Clinical Trials Arena
Wed, 03/1/23 - 10:05 am
Alzheimer's disease
Biogen
Eisai
Lundbeck
Otsuka
Avanir Pharmaceuticals
Axesome
Aduhelm
Leqembi
Billy Dunn, FDA’s top neuroscience official to depart agency
RAPS.org
Mon, 02/27/23 - 07:12 pm
Billy Dunn
FDA
Neurosciences
Biogen
Aduhelm
FDA adds warning of 'larger areas of bleeding' in brain to Biogen's Aduhelm label
Endpoints
Tue, 02/14/23 - 11:01 am
Biogen
Aduhelm
FDA
Alzheimer's disease
Eisai learns from Biogen’s Aduhelm disaster
EP Vantage
Mon, 01/9/23 - 10:35 am
Eisai
Biogen
Leqembi
Aduhelm
Alzheimer's disease
drug pricing
Biogen, FDA's inappropriate Aduhelm coordination detailed in blistering congressional report
Fierce Pharma
Fri, 12/30/22 - 10:50 am
Biogen
Aduhelm
Alzheimer's disease
FDA
US Congress
Lilly’s Donanemab Shines vs. Aduhelm in First Active Comparator Study
BioSpace
Thu, 12/1/22 - 07:10 pm
Eli Lilly
donanemab
clinical trials
Aduhelm
Biogen
Alzheimer's disease
Where Will Biogen Be in 5 Years?
Motley Fool
Thu, 10/20/22 - 10:39 am
Biogen
Aduhelm
lecanemab
Alzheimer's disease
M&A
Medicare Part B premiums to drop 3% next year, partly due to limited Aduhelm coverage
Medical Marketing and Media
Thu, 09/29/22 - 10:23 am
Medicare
Medicare Part B
Biogen
Aduhelm
Biogen nets $592M in Boston real estate sale as cost-cutting campaign rolls on
Fierce Pharma
Wed, 09/21/22 - 07:53 pm
Biogen
Aduhelm
Massachusetts
Boston
real estate
Cambridge
Aduhelm’s loss is a win for value-based drug pricing
MedCity News
Thu, 08/11/22 - 10:39 am
Biogen
Aduhelm
value-based pricing
drug pricing
Alzheimer's disease

Pages